Promises from Trametinib in RAF Active Tumors
Mené sur 322 patients atteints d'un mélanome métastatique présentant une mutation V600E ou V600K du gène BRAF, cet essai de phase III évalue, du point de vue de la survie sans progression et de la survie globale, le trametinib, un inhibiteur de MEK
Progression of human cancer occurs through genetic changes in cancer cells that activate biochemical pathways governing hallmarks of cancer, including proliferation and tumor-cell survival, among others. Tumor growth factor receptors activate RAS oncoproteins, which subsequently activate a kinase cascade that includes RAF, MEK, and ERK kinases. This pathway is mutated to promote tumor growth in at least 20% of cancers...
New England Journal of Medicine , éditorial en libre accès, 2011